Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease

PLoS Genetics

Volumn 13, Issue 3, 2017, Pages

  Kerr, Fiona ^a,g   Sofola Adesakin, Oyinkan ^a   Ivanov, Dobril K ^b   Gatliff, Jemma ^c   Gomez Perez Nievas, Beatriz ^d   Bertrand, Hélène C ^c   Martinez, Pedro ^a   Callard, Rebecca ^a,e   Snoeren, Inge ^a,e   Cochemé, Helena M ^f   Adcott, Jennifer ^a   Khericha, Mobina ^a,e   Castillo Quan, Jorge Iván ^a,e   Wells, Geoffrey ^c   Noble, Wendy ^d   Thornton, Janet ^b   Partridge, Linda ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e MAX PLANCK INSTITUTE FOR BIOLOGY OF AGEING   (Germany)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LITHIUM CHLORIDE; TRANSCRIPTION FACTOR NRF2; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); DROSOPHILA PROTEIN; GLYCOGEN SYNTHASE KINASE 3; KEAP1 PROTEIN, DROSOPHILA; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; OLEANOLIC ACID; PEPTIDE FRAGMENT; PROTEIN BINDING; THIADIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SYNAPTOTOXICITY; TOXICITY; TRANSCRIPTION INITIATION; XENOBIOTIC STRESS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CONFOCAL MICROSCOPY; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; LONGEVITY; METABOLISM; NERVE CELL; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC ANIMAL; TUMOR CELL LINE; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; GENE EXPRESSION PROFILING; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LITHIUM CHLORIDE; LONGEVITY; MICE; MICROSCOPY, CONFOCAL; NEURONS; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; PEPTIDE FRAGMENTS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIADIAZOLES; TRIAZOLES;

EID: 85016611018     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1006593     Document Type: Article

References (89)

1. Sykiotis GP, Bohmann D, (2010) Stress-activated cap'n'collar transcription factors in aging and human disease. Science signaling3: re3. doi: 10.1126/scisignal.3112re3 20215646
2. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. Journal of neuropathology and experimental neurology60: 759–767. 11487050
3. Sultana R, Butterfield DA, (2010) Role of oxidative stress in the progression of Alzheimer's disease. Journal of Alzheimer's disease: JAD19: 341–353. doi: 10.3233/JAD-2010-1222 20061649
4. Dias V, Junn E, Mouradian MM, (2013) The role of oxidative stress in Parkinson's disease. Journal of Parkinson's disease3: 461–491. doi: 10.3233/JPD-130230 24252804
5. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, et al. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America93: 2696–2701. 8610103
6. Floor E, Wetzel MG, (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. Journal of neurochemistry70: 268–275. 9422371
7. Gil-Mohapel J, Brocardo PS, Christie BR, (2014) The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?Current drug targets15: 454–468. 24428525
8. Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, et al. (2013) Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis & frontotemporal degeneration14Suppl 1: 19–32.
9. Williams AC, Steventon GB, Sturman S, Waring RH, (1991) Hereditary variation of liver enzymes involved with detoxification and neurodegenerative disease. J Inherit Metab Dis14: 431–435. 1749211
10. Pappolla MA, Omar RA, Chyan YJ, Ghiso J, Hsiao K, et al. (2001) Induction of NADPH cytochrome P450 reductase by the Alzheimer beta-protein. Amyloid as a "foreign body". J Neurochem78: 121–128. 11432979
11. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, et al. (2007) Expression of Nrf2 in neurodegenerative diseases. Journal of neuropathology and experimental neurology66: 75–85. doi: 10.1097/nen.0b013e31802d6da9 17204939
12. Sarlette A, Krampfl K, Grothe C, Neuhoff N, Dengler R, et al. (2008) Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. Journal of neuropathology and experimental neurology67: 1055–1062. doi: 10.1097/NEN.0b013e31818b4906 18957896
13. Kanninen K, Malm TM, Jyrkkanen HK, Goldsteins G, Keksa-Goldsteine V, et al. (2008) Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Molecular and cellular neurosciences39: 302–313. doi: 10.1016/j.mcn.2008.07.010 18706502
14. Karkkainen V, Pomeshchik Y, Savchenko E, Dhungana H, Kurronen A, et al. (2014) Nrf2 regulates neurogenesis and protects neural progenitor cells against Abeta toxicity. Stem Cells32: 1904–1916. doi: 10.1002/stem.1666 24753106
15. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA, (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci28: 13574–13581. doi: 10.1523/JNEUROSCI.4099-08.2008 19074031
16. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, et al. (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A106: 2933–2938. doi: 10.1073/pnas.0813361106 19196989
17. Kanninen K, Heikkinen R, Malm T, Rolova T, Kuhmonen S, et al. (2009) Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America106: 16505–16510. doi: 10.1073/pnas.0908397106 19805328
18. Liby K, Hock T, Yore MM, Suh N, Place AE, et al. (2005) The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer research65: 4789–4798. doi: 10.1158/0008-5472.CAN-04-4539 15930299
19. Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, et al. (2009) Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PloS one4: e5757. doi: 10.1371/journal.pone.0005757 19484125
20. Dumont M, Wille E, Calingasan NY, Tampellini D, Williams C, et al. (2009) Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. Journal of neurochemistry109: 502–512. doi: 10.1111/j.1471-4159.2009.05970.x 19200343
21. Abed DA, Goldstein M, Albanyan H, Jin H, Hu L, (2015) Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B5: 285–299. doi: 10.1016/j.apsb.2015.05.008 26579458
22. Bertrand HC, Schaap M, Baird L, Georgakopoulos ND, Fowkes A, et al. (2015) Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction. J Med Chem58: 7186–7194. doi: 10.1021/acs.jmedchem.5b00602 26348784
23. Tsakiri EN, Sykiotis GP, Papassideri IS, Terpos E, Dimopoulos MA, et al. (2013) Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. Aging cell12: 802–813. doi: 10.1111/acel.12111 23738891
24. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, et al. (2008) Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proceedings of the National Academy of Sciences of the United States of America105: 13568–13573. doi: 10.1073/pnas.0806268105 18757741
25. Cuadrado A, (2015) Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/beta-TrCP. Free Radic Biol Med88: 147–157. doi: 10.1016/j.freeradbiomed.2015.04.029 25937177
26. Llorens-Martin M, Jurado J, Hernandez F, Avila J, (2014) GSK-3beta, a pivotal kinase in Alzheimer disease. Front Mol Neurosci7: 46. doi: 10.3389/fnmol.2014.00046 24904272
27. Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, et al. (2013) Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem288: 1295–1306. doi: 10.1074/jbc.M112.409250 23155049
28. Koh SH, Kim Y, Kim HY, Hwang S, Lee CH, et al. (2007) Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol205: 336–346. doi: 10.1016/j.expneurol.2007.03.004 17433298
29. Morales-Garcia JA, Susin C, Alonso-Gil S, Perez DI, Palomo V, et al. (2013) Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci4: 350–360. doi: 10.1021/cn300182g 23421686
30. Youn P, Chen Y, Furgeson DY, (2015) Cytoprotection against beta-amyloid (Abeta) peptide-mediated oxidative damage and autophagy by Keap1 RNAi in human glioma U87mg cells. Neurosci Res94: 70–78. doi: 10.1016/j.neures.2014.12.015 25612817
31. Williamson TP, Johnson DA, Johnson JA, (2012) Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology33: 272–279. doi: 10.1016/j.neuro.2012.01.015 22342405
32. Wang B, Liu Q, Shan H, Xia C, Liu Z, (2015) Nrf2 inducer and cncC overexpression attenuates neurodegeneration due to alpha-synuclein in Drosophila. Biochem Cell Biol93: 351–358. doi: 10.1139/bcb-2015-0015 26008822
33. Barone MC, Sykiotis GP, Bohmann D, (2011) Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis Model Mech4: 701–707. doi: 10.1242/dmm.007575 21719443
34. Sofola O, Kerr F, Rogers I, Killick R, Augustin H, et al. (2010) Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS genetics6: e1001087. doi: 10.1371/journal.pgen.1001087 20824130
35. Sykiotis GP, Bohmann D, (2008) Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in Drosophila. Developmental cell14: 76–85. doi: 10.1016/j.devcel.2007.12.002 18194654
36. Burnouf S, Gorsky MK, Dols J, Gronke S, Partridge L, (2015) Abeta43 is neurotoxic and primes aggregation of Abeta40 in vivo. Acta Neuropathol130: 35–47. doi: 10.1007/s00401-015-1419-y 25862636
37. Casas-Tinto S, Zhang Y, Sanchez-Garcia J, Gomez-Velazquez M, Rincon-Limas DE, et al. (2011) The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Hum Mol Genet20: 2144–2160. doi: 10.1093/hmg/ddr100 21389082
38. Misra JR, Horner MA, Lam G, Thummel CS, (2011) Transcriptional regulation of xenobiotic detoxification in Drosophila. Genes & development25: 1796–1806.
39. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, et al. (2005) Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience132: 123–135. doi: 10.1016/j.neuroscience.2004.12.025 15780472
40. Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, et al. (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science345: 1192–1194. doi: 10.1126/science.1256800 25103406
41. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, et al. (2006) Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Molecular and cellular biology26: 2887–2900. doi: 10.1128/MCB.26.8.2887-2900.2006 16581765
42. Castillo-Quan JI, Li L, Kinghorn KJ, Ivanov DK, Tain LS, et al. (2016) Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis. Cell Rep15: 638–650. doi: 10.1016/j.celrep.2016.03.041 27068460
43. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, et al. (2011) (SCF/beta)-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Molecular and cellular biology31: 1121–1133. doi: 10.1128/MCB.01204-10 21245377
44. Ryves WJ, Harwood AJ, (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun280: 720–725. doi: 10.1006/bbrc.2000.4169 11162580
45. Chalecka-Franaszek E, Chuang DM, (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A96: 8745–8750. 10411946
46. Klein PS, Melton DA, (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A93: 8455–8459. 8710892
47. Sofola-Adesakin O, Castillo-Quan JI, Rallis C, Tain LS, Bjedov I, et al. (2014) Lithium suppresses Abeta pathology by inhibiting translation in an adult Drosophila model of Alzheimer's disease. Front Aging Neurosci6: 190. doi: 10.3389/fnagi.2014.00190 25126078
48. Veraksa A, McGinnis N, Li X, Mohler J, McGinnis W, (2000) Cap 'n' collar B cooperates with a small Maf subunit to specify pharyngeal development and suppress Deformed homeotic function in the Drosophila head. Development127: 4023–4037. 10952900
49. Rogers I, Kerr F, Martinez P, Hardy J, Lovestone S, et al. (2012) Ageing increases vulnerability to abeta42 toxicity in Drosophila. PloS one7: e40569. doi: 10.1371/journal.pone.0040569 22808195
50. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, et al. (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nature cell biology12: 213–223. doi: 10.1038/ncb2021 20173742
51. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, et al. (2013) Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Molecular cell51: 618–631. doi: 10.1016/j.molcel.2013.08.003 24011591
52. Fan W, Tang Z, Chen D, Moughon D, Ding X, et al. (2010) Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy6: 614–621. doi: 10.4161/auto.6.5.12189 20495340
53. Grimberg KB, Beskow A, Lundin D, Davis MM, Young P, (2011) Basic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the Drosophila 26S proteasome. Molecular and cellular biology31: 897–909. doi: 10.1128/MCB.00799-10 21149573
54. Dinkova-Kostova AT, Talalay P, Sharkey J, Zhang Y, Holtzclaw WD, et al. (2010) An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. J Biol Chem285: 33747–33755. doi: 10.1074/jbc.M110.163485 20801881
55. Wang YY, Yang YX, Zhe H, He ZX, Zhou SF, (2014) Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther8: 2075–2088. doi: 10.2147/DDDT.S68872 25364233
56. Hancock R, Bertrand HC, Tsujita T, Naz S, El-Bakry A, et al. (2012) Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction. Free Radic Biol Med52: 444–451. doi: 10.1016/j.freeradbiomed.2011.10.486 22107959
57. Hancock R, Schaap M, Pfister H, Wells G, (2013) Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity. Org Biomol Chem11: 3553–3557. doi: 10.1039/c3ob40249e 23615671
58. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature416: 535–539. doi: 10.1038/416535a 11932745
59. DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, et al. (2012) Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis45: 425–437. doi: 10.1016/j.nbd.2011.09.002 21945540
60. Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, et al. (2015) Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. Nat Commun6: 7066. doi: 10.1038/ncomms8066 25967870
61. Niccoli T, Partridge L, (2012) Ageing as a risk factor for disease. Curr Biol22: R741–752. doi: 10.1016/j.cub.2012.07.024 22975005
62. Joshi G, Gan KA, Johnson DA, Johnson JA, (2015) Increased Alzheimer's disease-like pathology in the APP/ PS1DeltaE9 mouse model lacking Nrf2 through modulation of autophagy. Neurobiol Aging36: 664–679. doi: 10.1016/j.neurobiolaging.2014.09.004 25316599
63. Johnson DA, Johnson JA, (2015) Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med88: 253–267. doi: 10.1016/j.freeradbiomed.2015.07.147 26281945
64. Kim HV, Kim HY, Ehrlich HY, Choi SY, Kim DJ, et al. (2013) Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid20: 7–12. doi: 10.3109/13506129.2012.751367 23253046
65. Ding H, Wang H, Zhao Y, Sun D, Zhai X, (2015) Protective Effects of Baicalin on Abeta(1)(-)(4)(2)-Induced Learning and Memory Deficit, Oxidative Stress, and Apoptosis in Rat. Cell Mol Neurobiol35: 623–632. doi: 10.1007/s10571-015-0156-z 25596671
66. Yu L, Wang S, Chen X, Yang H, Li X, et al. (2015) Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer's disease. Life Sci121: 104–109. doi: 10.1016/j.lfs.2014.11.021 25497709
67. Cao H, Wang L, Chen B, Zheng P, He Y, et al. (2015) DNA Demethylation Upregulated Nrf2 Expression in Alzheimer's Disease Cellular Model. Front Aging Neurosci7: 244. doi: 10.3389/fnagi.2015.00244 26779013
68. Tanaka N, Ikeda Y, Ohta Y, Deguchi K, Tian F, et al. (2011) Expression of Keap1-Nrf2 system and antioxidative proteins in mouse brain after transient middle cerebral artery occlusion. Brain Res1370: 246–253. doi: 10.1016/j.brainres.2010.11.010 21075092
69. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, et al. (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci27: 1981–1991. doi: 10.1523/JNEUROSCI.4321-06.2007 17314294
70. Noble W, Planel E, Zehr C, Olm V, Meyerson J, et al. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A102: 6990–6995. doi: 10.1073/pnas.0500466102 15867159
71. Eldar-Finkelman H, Martinez A, (2011) GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci4: 32. doi: 10.3389/fnmol.2011.00032 22065134
72. Lovestone S, Boada M, Dubois B, Hull M, Rinne JO, et al. (2015) A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis45: 75–88. doi: 10.3233/JAD-141959 25537011
73. Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, et al. (2014) Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med67: 387–395. doi: 10.1016/j.freeradbiomed.2013.11.014 24355211
74. Alural B, Ozerdem A, Allmer J, Genc K, Genc S, (2015) Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells. Front Cell Neurosci9: 209. doi: 10.3389/fncel.2015.00209 26074776
75. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, et al. (2003) Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol23: 7198–7209. doi: 10.1128/MCB.23.20.7198-7209.2003 14517290
76. Digaleh H, Kiaei M, Khodagholi F, (2013) Nrf2 and Nrf1 signaling and ER stress crosstalk: implication for proteasomal degradation and autophagy. Cell Mol Life Sci70: 4681–4694. doi: 10.1007/s00018-013-1409-y 23800989
77. Spires-Jones TL, Hyman BT, (2014) The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron82: 756–771. doi: 10.1016/j.neuron.2014.05.004 24853936
78. Eftekharzadeh B, Maghsoudi N, Khodagholi F, (2010) Stabilization of transcription factor Nrf2 by tBHQ prevents oxidative stress-induced amyloid beta formation in NT2N neurons. Biochimie92: 245–253. doi: 10.1016/j.biochi.2009.12.001 20026169
79. Lee C, Park GH, Lee SR, Jang JH, (2013) Attenuation of beta-amyloid-induced oxidative cell death by sulforaphane via activation of NF-E2-related factor 2. Oxid Med Cell Longev2013: 313510. doi: 10.1155/2013/313510 23864927
80. Jhang KA, Lee EO, Kim HS, Chong YH, (2014) Norepinephrine provides short-term neuroprotection against Abeta1-42 by reducing oxidative stress independent of Nrf2 activation. Neurobiol Aging35: 2465–2473. doi: 10.1016/j.neurobiolaging.2014.05.020 24954831
81. Zou Y, Hong B, Fan L, Zhou L, Liu Y, et al. (2013) Protective effect of puerarin against beta-amyloid-induced oxidative stress in neuronal cultures from rat hippocampus: involvement of the GSK-3beta/Nrf2 signaling pathway. Free Radic Res47: 55–63. doi: 10.3109/10715762.2012.742518 23088308
82. Ling D, Salvaterra PM, (2011) Robust RT-qPCR data normalization: validation and selection of internal reference genes during post-experimental data analysis. PLoS One6: e17762. doi: 10.1371/journal.pone.0017762 21423626
83. Kerr F, Augustin H, Piper MD, Gandy C, Allen MJ, et al. (2011) Dietary restriction delays aging, but not neuronal dysfunction, in Drosophila models of Alzheimer's disease. Neurobiol Aging32: 1977–1989. doi: 10.1016/j.neurobiolaging.2009.10.015 19969390
84. Schuster EF, Blanc E, Partridge L, Thornton JM, (2007) Correcting for sequence biases in present/absent calls. Genome Biol8: R125. doi: 10.1186/gb-2007-8-6-r125 17594492
85. Gautier L, Cope L, Bolstad BM, Irizarry RA, (2004) affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics20: 307–315. doi: 10.1093/bioinformatics/btg405 14960456
86. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, et al. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res43: e47. doi: 10.1093/nar/gkv007 25605792
87. Breslin T, Eden P, Krogh M, (2004) Comparing functional annotation analyses with Catmap. BMC Bioinformatics5: 193. doi: 10.1186/1471-2105-5-193 15588298
88. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science274: 99–102. 8810256
89. Hudry E, Wu HY, Arbel-Ornath M, Hashimoto T, Matsouaka R, Fan Z, Spires-Jones TL, Betensky RA, Bacskai B J, Hyman BT,. (2012) Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease. J. Neuroscience32: 3176–3192. doi: 10.1523/JNEUROSCI.6439-11.2012 22378890